

Nebraska Medicaid DUR Board Meeting
Tuesday November 10, 2009
DRAFT pending approval at January meeting

The Nebraska Medicaid DUR Board met on Tuesday, November 10, 2009 at the Country Inn and Suites in Lincoln.

DUR Board Members in Attendance:

Kevin Borchert, R.P.
Lynn Carlson, R.P.
Elissa Carney, R.P.
Shana Castillo, R.P.
Karsen Duncan, PharmD. Candidate UNMC
Eric Gall, R.P.
Nicole Gillespie, PharmD. Candidate CU
Bruce Houghton, M.D.
David Hutsell, R.P.
Norman Kelley, M.D.
Charlie Moore, R.P.
Marcia Muetting, R.P., Nebraska DUR Director
Phil Vuchetich, R.P.
Robert Wergin, M.D.

DUR Board Members Absent:

Susan Howard, M.D.
Kirk Muffly, M.D.

Guests in Attendance:

Barbara Dowd, R.P. First Health Services Corporation
Nazifa Obaidi, PharmD. Candidate UNMC
Barb Mart, R.P. Nebraska Medicaid

Public Members in Attendance:

Jeff Knappen, Allergan
Stephanie Miller, Amgen
George Stamboulieh, Cephalon
Roxanne Meyer, Centocor/J&J
Carol Curtis, AstraZeneca
Patti Wingbermuehle, AstraZeneca
Ronnie DePue, Forest
Don Larson, Forest
Dave Walters, J&J
Susan Zalenski, J&J
Joe Busby, Lilly
Brian Reichmuth, Lilly
Barbara Belcher, Merck
Patty Loughlin, Strativa

I. Opening and Introductions

The meeting was called to order at 6:30 pm. Introductions were made by the public members attending, DUR Board members, and guests in attendance. The director noted that a copy of the Open Meeting Laws is available on the front table along with a copy of all meeting materials.

II. Declaration of any Conflict of Interest or changes

None

III. Review of Agenda

The director noted that two items should be removed from the agenda, Old Business under Prospective DUR and Review of Prior Authorization for Vyvanse under New Business, Prospective DUR. A motion to accept the agenda as amended was made by Eric Gall with a second from Kevin Borchert. Vote as follows: Borchert-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Hutsell-yes, Kelley-yes, Moore-yes, Vuchetich-yes and Wergin-yes. Motion carried.

IV. Review of minutes from September meeting

A motion to accept the minutes as written was made by Norman Kelley with a second from Bob Wergin. Vote as follows: Borchert-yes, Carlson-yes, Carney-abstain, Castillo-yes, Gall-yes, Houghton-yes, Hutsell-yes, Kelley-yes, Moore-yes, Vuchetich-abstain and Wergin-yes. Motion carried.

V. Retrospective DUR

A. Current Profile Review

1. Lock Ins

The director reported that 5 patients were being evaluated for lock in, which resulted in 86 letters to prescribers and pharmacies with a 41% response rate.

2. Patients taking 2 or more serotonergic drugs

The director noted that profiles were recently mailed to Board Members and details of the project will be shared at the next meeting.

3. Patients taking >3200 mg ibuprofen daily

The director noted that the profile review resulted in 100% false negatives. There were no patients taking ibuprofen on a continual basis, but patients met the criteria due to one or two prescriptions. The majority of the patients were receiving ibuprofen post-partem or after dental procedures for short-term use.

B. Old Business

1. Non-Compliance on Statin Therapy

Barbara Dowd reported that 200 profiles were reviewed and 69 letters were sent to prescribers. There were 21 responses. Nine indicated that the intervention was useful and seven indicated that it was not useful. Eight noted that they will counsel the patient and two will discontinue the medication. Two prescribers noted that the patient will be tagged for monitoring and one will reassess therapy and monitor.

C. Recommendations for Future Profile Reviews

Board member discussion resulted in a recommendation to review profiles of patients taking methodone and fluoroquinolones concomitantly and patients utilizing multiple providers to obtain controlled substances.

VI. Prospective DUR

A. New Business

1. DUR Board review of New Drug Products to determine if Prior Authorization is appropriate

a. Nuvigil

Public comment was offered by George Stamboulieh. He noted that Nuvigil is the longer-lasting enantiomer of modafinil with a higher Cmax and greater AUC. Barbara Dowd reported that there had been six requests with one being approved. A motion was made to remove the Prior Authorization by Bruce Houghton with a second from Norman Kelley. Vote as follows: Borchert-no, Carlson-no, Carney-no, Castillo-no, Gall-no, Houghton-yes, Hutsell-yes, Kelley-yes, Moore-no, Vuchetich-yes and Wergin-yes. Motion failed. A motion was made to develop criteria for the drug class, based on profile review by Kevin Borchert with a second from Phil Vuchetich. Vote as

follows: Borchert-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Hutsell-yes, Kelley-no, Moore-yes, Vuchetich-yes and Wergin-yes. Motion carried.

b. Savella

Public comment was offered by Ronnie DePue. He stated that SSRIs and TCAs have limited benefit for the treatment of fibromyalgia. Savella, an SNRI, has a three times greater preference for blocking reuptake of norepinephrine over serotonin. Barbara Dowd reported that prior authorization for Savella was approved in 28 patients and denied in three patients. Nazifa Obaidi reported that a profile review had been performed on all approved requests for Savella. These patients were found to be very complex with many diagnoses. Many patients were not taking a SSRI prior to initiation of Savella and in those who were, there was no decrease in use of SSRIs after initiation of Savella. Several patients only had one claim for Savella. A motion was made to recommend removal of the prior authorization with a quantity limit of two tablets per day for all strengths by Shana Castillo with a second from Eric Gall. Vote as follows: Borchert-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Hutsell-yes, Kelley-yes, Moore-yes, Vuchetich-yes and Wergin-yes. Motion carried.

c. Simponi

Public comment was offered by Roxanne Meyer. She noted that Simponi is indicated for adults with RA, Psoriatic Arthritis or Ankylosing Spondylitis. Simponi is the only anti-TNF that is dosed once per month and does not require induction dosing. Simponi is given as a fixed dose with no dose escalation required. It is supplied in a specially designed auto-injector for patients with arthritis. The director noted that the AWP cost supplied in the monograph information should be \$1890 instead of \$3937 per dose. A motion was made to recommend removal of the prior authorization with a quantity limit of one injection per 30 days by David Hutsell with a second from Bruce Houghton. Vote as follows: Borchert-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Hutsell-yes, Kelley-yes, Moore-yes, Vuchetich-yes and Wergin-yes. Motion carried.

2. Annual Review of Prior Authorization Criteria

a. Growth Hormone

Barbara Dowd stated that in one year there were 70 approvals for 30 recipients and 14 denials for 12 recipients. Barb Mart noted that the requirement for open epiphysis appears on the criteria but not on the prior authorization request form. A motion was made to recommend adding "epiphysis open Y/N" to the prior authorization form under Diagnostic Testing by Shana Castillo with a second from Eric Gall. Vote as follows: Borchert-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Hutsell-yes, Kelley-yes, Moore-yes, Vuchetich-yes and Wergin-yes. Motion carried.

b. IGF-1

The director noted she was not aware of any changes to the indications for IGF-1 or the treatment guidelines. A motion was made to recommend that no change be made to the PA criteria by Kevin Borchert with a second from Eric Gall. Vote as follows: Borchert-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Hutsell-yes, Kelley-yes, Moore-yes, Vuchetich-yes and Wergin-yes. Motion carried.

VII. Special Requests from the Department

None

VIII. Future Meeting Dates

January 12

March 9

May 11

July 13

September 14

November 9

IX. Concerns and Comments from:

Board

None

Director

None

State Representatives

Barb Mart noted that with the state budget concerns she recognizes that the DUR Board members and Medicaid providers have facilitated cost effective care. She voiced her appreciation for the efforts of the DUR Board to decrease costs in the Medicaid program.

X. Adjournment

A motion to adjourn at 8:40 pm was made by Norman Kelley with a second from Kevin Borchert. Vote as follows: Borchert-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Hutsell-yes, Kelley-yes, Moore-yes, Vuchetich-yes and Wergin-yes. Motion carried.